Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery
- 5 August 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 14 (4) , 513-523
Abstract
Introduction: Neurodegenerative diseases (NDs) represent a group of different clinical entities that, despite the specific primary etiologies, share a common signature in terms of a general mitochondrial dysfunction with consequent oxidative stress accumulation. As these two events occur early during neurodegenerative process, they could be considered ideal therapeutic targets. Areas covered: This review describes the nanotechnologies explored for the specific targeted delivery of drugs, in order to precisely direct molecules into the intended site, where they can practice their therapeutic effects. Expert opinion: Conventional drug delivery systems cannot provide adequate restoration and connection patterns that are essential for a functional recovery in NDs. Since orally delivered antioxidants are easily destroyed by acids and enzymes, only a small portion of consumed antioxidants gets absorbed, leading to low bioavailability and low concentration at the target site. In this scenario, the identification of new proenergetic drugs, in combination with the development of methods for selectively delivering biologically active molecules into mitochondria, will potentially launch new therapeutic approaches for the treatment of NDs, where energetic imbalance plays a central role.Keywords
This publication has 81 references indexed in Scilit:
- Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeuticsProceedings of the National Academy of Sciences, 2012
- The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's DiseaseThe Journal of Neuroscience, 2011
- Cerium Oxide Nanoparticles Inhibits Oxidative Stress and Nuclear Factor-κB Activation in H9c2 Cardiomyocytes Exposed to Cigarette Smoke ExtractThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease modelFree Radical Biology and Medicine, 2010
- Dual Beneficial Effects of (-)-Epigallocatechin-3-Gallate on Levodopa Methylation and Hippocampal Neurodegeneration: In Vitro and In Vivo StudiesPLOS ONE, 2010
- Current advances in research and clinical applications of PLGA-based nanotechnologyExpert Review of Molecular Diagnostics, 2009
- CoQ10 deficiency diseases in adultsMitochondrion, 2007
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006
- Cerium and yttrium oxide nanoparticles are neuroprotectiveBiochemical and Biophysical Research Communications, 2006
- Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondriaMitochondrion, 2005